Enoxaparin in acute coronary syndromes: Evidence for superiority over placebo or untreated control

American Heart Journal

Volumn 143, Issue 5, 2002, Pages 748-752

  Massel, David ^a   Cruickshank, Moira K ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; PLACEBO;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HEPARINIZATION; HUMAN; MORTALITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0036271667     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.121808     Document Type: Article

References (25)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction
3. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
4. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis
5. Meta-analysis in clinical trials
6. Unfractionated heparin and low-molecular weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
7. Low-molecular-weight heparins
8. Heparin and low-molecular-weight heparin: Mechanism of action, dosing, considerations, monitoring, efficacy, and safety
9. Low-molecular-weight heparin: A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina
10. LMWH versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
11. Low-molecular-weight heparin during instability in coronary artery disease
12. Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study
13. Fragmin in unstable coronary artery disease study: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease
14. A comparison of low-molecular-weight heparin with UFH far unstable coronary artery disease: Efficacy and Safety of Subcutaneous enoxaparin in Non-Q-Wave Coronary Events Study Group
15. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) IIB trial
16. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome)
17. Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo
18. Beta blockade during and after MI: An overview of the randomized trials
19. Aspirin, heparin, or both to treat acute unstable angina
20. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group)
21. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
22. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial
23. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina
24. Assessment of the treatment effect of enoxaparin far unstable angina/non-Q-wave myocardial infarction: TIMI1 1B-ESSENCE meta-analysis
25. Bayesian design and analysis of active control clinical trials